Distribution of TP63 rearrangements by PTCL subtype
| PTCL subtype . | Cases studied, n (%) . | TP63 rearrangement, n/tested (%) . | TBL1XR1 partner, n/tested (%) . |
|---|---|---|---|
| Angioimmunoblastic TCL | 38 (20.0) | 0/38 (0.0) | — (—) |
| PTCL, NOS | 53 (27.9) | 5/53 (9.4) | 3/5 (60.0) |
| ALCL, ALK positive | 21 (11.1) | 0/21 (0.0) | — (—) |
| ALCL, ALK negative | 32 (16.8) | 4/32 (12.5) | 3/4 (75.0) |
| ALCL, primary cutaneous | 19 (10.0) | 2/19 (10.5) | 1/2 (50.0) |
| Mycosis fungoides* | 7 (3.9) | 0/7 (0.0) | — (—) |
| Enteropathy-associated TCL | 4 (2.1) | 0/4 (0.0) | — (—) |
| Hepatosplenic TCL | 1 (0.5) | 0/1 (0.0) | — (—) |
| SCPTCL | 1 (0.5) | 0/1 (0.0) | — (—) |
| LGL | 5 (2.6) | 0/5 (0.0) | — (—) |
| NKTL | 9 (4.7) | 0/9 (0.0) | — (—) |
| Total | 190 (100.0) | 11/190 (5.8) | 7/11 (63.6) |
| PTCL subtype . | Cases studied, n (%) . | TP63 rearrangement, n/tested (%) . | TBL1XR1 partner, n/tested (%) . |
|---|---|---|---|
| Angioimmunoblastic TCL | 38 (20.0) | 0/38 (0.0) | — (—) |
| PTCL, NOS | 53 (27.9) | 5/53 (9.4) | 3/5 (60.0) |
| ALCL, ALK positive | 21 (11.1) | 0/21 (0.0) | — (—) |
| ALCL, ALK negative | 32 (16.8) | 4/32 (12.5) | 3/4 (75.0) |
| ALCL, primary cutaneous | 19 (10.0) | 2/19 (10.5) | 1/2 (50.0) |
| Mycosis fungoides* | 7 (3.9) | 0/7 (0.0) | — (—) |
| Enteropathy-associated TCL | 4 (2.1) | 0/4 (0.0) | — (—) |
| Hepatosplenic TCL | 1 (0.5) | 0/1 (0.0) | — (—) |
| SCPTCL | 1 (0.5) | 0/1 (0.0) | — (—) |
| LGL | 5 (2.6) | 0/5 (0.0) | — (—) |
| NKTL | 9 (4.7) | 0/9 (0.0) | — (—) |
| Total | 190 (100.0) | 11/190 (5.8) | 7/11 (63.6) |
TCL indicates T-cell lymphoma; PTCL, peripheral TCL; NOS, not otherwise specified; ALCL, anaplastic large-cell lymphoma; ALK, anaplastic lymphoma kinase; SCPTCL, subcutaneous panniculitis-like TCL; LGL, T-cell large granular lymphocytic leukemia; —, not applicable; and NKTL, extranodal NK/TCL, nasal type.
Including 2 cases with large-cell transformation.